Related Experiment Video
Updated: May 25, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Enhancing CHK1 inhibitor lethality in glioblastoma
Yong Tang1, Yun Dai, Steven Grant
1Department of Neurosurgery, School of Medicine, Virginia Commonwealth University; Richmond, VA, USA.
Abstract:
The present studies were initiated to determine whether inhibitors of MEK1/2 or SRC signaling, respectively, enhance CHK1 inhibitor lethality in primary human glioblastoma cells. Multiple MEK1/2 inhibitors (CI-1040 (PD184352); AZD6244 (ARRY-142886)) interacted with multiple CHK1 inhibitors (UCN-01, AZD7762) to kill multiple primary human glioma cell isolates that have a diverse set of genetic alterations typically found in the disease. Inhibition of SRC family proteins also enhanced CHK1 inhibitor lethality. Combined treatment of glioma cells with (MEK1/2 + CHK1) inhibitors enhanced radiosensitivity. Combined (MEK1/2 + CHK1) inhibitor treatment led to dephosphorylation of ERK1/2 and S6 ribosomal protein, whereas the phosphorylation of JNK and p38 was increased. MEK1/2 + CHK1 inhibitor-stimulated cell death was associated with the cleavage of pro-caspases 3 and 7 as well as the caspase substrate (PARP). We also observed activation of pro-apoptotic BCL-2 effector proteins BAK and BAX and reduced levels of pro-survival BCL-2 family protein BCL-XL. Overexpression of BCL-XL alleviated but did not completely abolish MEK1/2 + CHK1 inhibitor cytotoxicity in GBM cells. These findings argue that multiple inhibitors of the SRC-MEK pathway have the potential to interact with multiple CHK1 inhibitors to kill glioma cells.
Insights
Targeting MEK1/2 or SRC pathways with inhibitors synergizes with CHK1 inhibitors to kill glioblastoma cells. This combination therapy also enhances radiosensitivity and induces apoptosis in glioma cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Glioblastoma (GBM) remains a lethal brain cancer with limited treatment options.
- Targeting cell cycle regulators like CHK1 is a potential therapeutic strategy.
- Understanding resistance mechanisms and combination therapies is crucial for improving GBM treatment.
Purpose of the Study:
- To investigate if MEK1/2 or SRC signaling inhibitors enhance the lethality of CHK1 inhibitors in primary human glioblastoma cells.
- To explore the combined effects of MEK1/2 and CHK1 inhibitors on glioma cell radiosensitivity and apoptosis.
- To elucidate the molecular mechanisms underlying the synergistic cell death induced by these combined inhibitors.
Main Methods:
- Utilized multiple MEK1/2 inhibitors (CI-1040, AZD6244) and CHK1 inhibitors (UCN-01, AZD7762) in primary human glioma cell lines.
- Assessed cell viability and apoptosis markers (caspase cleavage, PARP, BCL-2 family proteins).
- Investigated effects on signaling pathways (ERK1/2, S6, JNK, p38) and radiosensitivity.
Main Results:
- MEK1/2 and SRC inhibitors significantly enhanced CHK1 inhibitor-induced lethality in diverse human glioma cells.
- Combined MEK1/2 + CHK1 inhibition increased radiosensitivity and promoted apoptosis via caspase activation and BCL-2 family modulation.
- Treatment led to dephosphorylation of ERK1/2/S6 and increased JNK/p38 phosphorylation, with BCL-XL overexpression partially rescuing cytotoxicity.
Conclusions:
- Inhibitors targeting SRC-MEK pathways can synergize with CHK1 inhibitors to effectively kill glioma cells.
- This combination strategy holds promise for enhancing glioblastoma treatment outcomes, including radiosensitization.
- The findings support the development of dual SRC-MEK and CHK1 inhibitor therapies for glioblastoma.
